Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | FABP4 | P15090 | 2/20 | 0.46 |
| ▸ | FABP3 | P05413 | 1/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL856314 | 0.84 | NPC1 (0.57) | KDM4EPOLBATMKMT2AAKR1C3 | |
| SCHEMBL4501464 | 0.83 | KDM4E (0.41) | PBRM1KDM4EPOLBATMFABP4 | |
| SCHEMBL11704682 | 0.82 | PBRM1 (0.50) | PBRM1KDM4EFABP4FABP3FABP5 | |
| SCHEMBL12041920 | 0.82 | PBRM1 (0.54) | PBRM1KDM4EFABP4FABP3FABP5 | |
| N-Methylanthranilic Acid SCHEMBL130356 | 0.81 | KDM4E (0.64) | KDM4EPOLBATMFABP4FABP3 | |
| N-Methylanthranilic Acid SCHEMBL29381752 | 0.81 | KDM4E (0.64) | KDM4EPOLBATMFABP4FABP3 | |
| SCHEMBL11593694 | 0.81 | POLB (0.56) | PBRM1KDM4EPOLBKMT2AAKR1C3 | |
| SCHEMBL30346643 | 0.81 | POLB (0.56) | PBRM1KDM4EPOLBKMT2AAKR1C3 | |
| SCHEMBL16318050 | 0.80 | KDM4E (0.54) | KDM4EPOLBFABP4FABP3KMT2A | |
| SCHEMBL9472562 | 0.80 | PBRM1 (0.49) | PBRM1KDM4EPOLBFABP4FABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2519467-B1 | MODULAR BIOCOMPATIBLE MATERIALS FOR MEDICAL DEVICES AND USES THEREOF | UNIV COLORADO STATE RES FOUND (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10266408-B2 | Modular biocompatible materials for medical devices and uses thereof | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2019-04-23 | — | — | US | disclosed |
| WO-2017033206-A2 | SOLID STATE FORMS OF N-[2-[(1 S)-1 -(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYL SULFONYL)ETHYL]-2,3-DIHYDRO-1,3-DIOXO-L H-ISOINDOL-4-YL]ACETAMIDE AND PROCESS FOR PREPARATION THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-03-02 | — | — | WO | disclosed |
| US-9493352-B2 | Modular biocompatible materials for medical devices and uses thereof | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150118268-A1 | MODULAR BIOCOMPATIBLE MATERIALS FOR MEDICAL DEVICES AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2015-04-30 | — | — | US | disclosed |
| US-9018243-B2 | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof | CELGENE CORPORATION (US) | 2015-04-28 | — | — | US | disclosed |
| CN-103917344-A | Methods of treating wood with preservatives using supercritical noble gases | EMPIRE TECHNOLOGY DEV LLC | 2014-07-09 | — | — | CN | disclosed |
| US-8771756-B2 | Biocompatible materials for medical devices | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-07-08 | — | — | US | disclosed |
| US-20140178504-A1 | MODULAR BIOCOMPATIBLE MATERIALS FOR MEDICAL DEVICES AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-06-26 | — | — | US | disclosed |
| US-8629173-B2 | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof | CELGENE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| EP-2519467-A1 | MODULAR BIOCOMPATIBLE MATERIALS FOR MEDICAL DEVICES AND USES THEREOF | Colorado State University Research Foundation (US) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011082164-A1 | MODULAR BIOCOMPATIBLE MATERIALS FOR MEDICAL DEVICES AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110159116-A1 | BIOCOMPATIBLE MATERIALS FOR MEDICAL DEVICES | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150118268-A1 | MODULAR BIOCOMPATIBLE MATERIALS FOR MEDICAL DEVICES AND USES THEREOF | NOS3, NOS1, NOS2 | PBRM1 790/4885KDM4E 2212/4885POLB 2571/4885 |
| US-10266408-B2 | Modular biocompatible materials for medical devices and uses thereof | NOS3, NOS1, NOS2 | PBRM1 790/4885KDM4E 2212/4885POLB 2571/4885 |
| US-20140178504-A1 | MODULAR BIOCOMPATIBLE MATERIALS FOR MEDICAL DEVICES AND USES THEREOF | NOS2, NOS3, NOS1 | PBRM1 2948/4885KDM4E 2901/4885POLB 4404/4885 |
| US-20110159116-A1 | BIOCOMPATIBLE MATERIALS FOR MEDICAL DEVICES | NOS2, NOS3, NOS1 | PBRM1 3816/4885KDM4E 2787/4885POLB 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.